Movement Alert|Regeneron Pharmaceuticals Falls 3.46% in Pre-Market Trading, Shares Pull Back After CIDEBsiRNA Data-Driven Rally

Market Focus11-11

On November 11, Regeneron Pharmaceuticals fell 3.46% in Pre-Market Trading to $884.41 per share, with turnover of $3.4917 million.

The latest market-moving context points to a pullback after the company’s recently disclosed early clinical data for its liver-targeted siRNA candidate CIDEBsiRNA had lifted sentiment and supported gains in the prior session.

The company reported that a single subcutaneous dose reduced liver fat by 58% to 80% at week 36 with a dose-dependent effect, versus a 2.9% decline in the placebo group. In addition, 93% of participants achieved at least a 30% reduction in liver fat, while ALT and AST liver injury markers continued to improve. Those data were presented recently and had already helped drive the stock higher, making the current pre-market weakness more consistent with short-term retracement after a news-led advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment